retatrutide maximum dose clinical trials in adults with obesity over 104 weeks in the highest group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 The Effect of Retatrutide on

For insured patients, copays for the pill and injection should be similar once both are on formulary

Common side effects include nausea, vomiting, and diarrhea

Frequently Asked Questions (FAQs) Q1: What are the most common GLP-1 side effects

Why are we talking about GLP-1 agonists now

K ATP , channel ATP-sensitive potassium channel, MBF, microvascular blood flow

Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment